“Spray Vaccine for Flu Wins FDA Clearance”

Return to Vaccination News Home Page

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.

The U.S. Food and Drug Administration has approved MedImmune’s FluMist, the first influenza vaccine intended to be sprayed into the nose instead of injected into the arm, and it is expected to be available in time for this year’s flu season. Doctors hope that the inhaled vaccine--which is approved for those between the ages of five and 49 years, a population that tends to avoid the flu shot--will increase the number of healthy people who get vaccinated and also free up the supply of the injected vaccine. The new vaccine is expected to cost $46 per dose, and while MedImmune will only produce up to 6 million doses this year due to manufacturing constraints, analysts think that the company will be able to sell them all. The agency has not approved FluMist for those with respiratory diseases or asthma, and because it contains a diluted live virus, it could be risky for people with weakened immune systems. MedImmune is planning to conduct more tests so it can get the vaccine approved for the elderly and the very young.

Return to Vaccination News Home Page

DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.